INTRODUCTION {#s1}
============

Coronary heart disease (CHD), is a major cause of morbidity and mortality worldwide \[[@R1]\] and one of the most common chronic inflammatory diseases, characterized by remodeling and narrowing of the blood vessels (coronary arteries) that supply oxygen and blood to the heart \[[@R2]\]. CHD is a complex disease influenced by both environmental and genetic factors \[[@R3], [@R4]\]. Epidemiological studies have identified many risk factors for CHD, including age, gender, smoking, obesity, diabetes, hyperlipidemia, hypertension, lack of exercise, and dietary factors. Twin and family studies have demonstrated that a significant proportion (40-50%) of susceptibility to CHD is inherited \[[@R5]\]. Although atherosclerosis is one of the main pathophysiological mechanisms of CHD \[[@R2]\], the responsible molecular and genetic determinants remain largely unidentified. Recently, both genome-wide association studies (GWAS) and candidate gene studies have reported that *CDKN2BAS* (cyclin-dependent kinase inhibitor 2B antisense RNA) is a risk gene for CHD susceptibility \[[@R6]--[@R8]\].

*CDKN2BAS* encodes an antisense non-coding RNA, and is located near the *CDKN2A*-*CDKN2B* gene. The precise function of *CDKN2BAS* is unclear, but it regulates the expression of neighboring protein-coding genes, like *CDKN2A*, *CDKN2B*, and *MTAP*, that enhance the progression of atherosclerosis by influencing vascular remodeling, thrombogenesis, and plaque stability \[[@R9], [@R10]\]. Therefore, *CDKN2BAS* expression plays a pivotal role in the development of CHD by altering the dynamics of vascular cell proliferation. In addition, single nucleotide polymorphisms (SNPs) in *CDKN2BAS* are associated with the risk of multiple diseases, including comprising CHD \[[@R7], [@R9], [@R11]\], myocardial infarction \[[@R7]\], type 2 diabetes \[[@R12]\], ischemic stroke \[[@R13]\], and periodontitis \[[@R14]\].

While many studies have demonstrated that polymorphisms in *CDKN2BAS*are associated with the risk of CHD, few studies have focused on the effects of these alterations on susceptibility to CHD in the Han Chinese population. Therefore, we performed a case-control study to investigate the associations between these SNPs and the risk of CHD in the Han Chinese men and women.

RESULTS {#s2}
=======

Basic information on the eight SNPs in *CDKN2BAS*, including chromosomal position, role, allele, minor allele frequency (MAF), and Hardy-Weinberg Equilibrium (HWE) test results are shown in Table [1](#T1){ref-type="table"}. All SNPs were in HWE in the control groups (*P* \> 0.05). We then compared the differences in frequency distributions of alleles between cases and controls using Chi-squared tests and found that the frequency of allele "G" of rs10757274 in *CDKN2BAS* was higher in cases, and it was associated with a 1.30-fold increased risk of CHD in men at a 5% level (OR = 1.30, 95% CI: 1.05-1.61, *P* = 0.018).

###### Allele frequencies in cases and controls and odds ratio estimates for CHD

  SNP-ID       Gene       Chr   Band     Position   Role     Alleles (A/B)   Men     Women                                                                                 
  ------------ ---------- ----- -------- ---------- -------- --------------- ------- ------- ------- ------ ----------- ------- ------- ------- ------- ------ ----------- -------
  rs7865618    CDKN2BAS   9     9p21.3   22031005   Intron   G/A             0.116   0.132   0.827   0.86   0.62-1.19   0.352   0.139   0.105   1.000   1.38   0.92-2.07   0.119
  rs11790231   CDKN2BAS   9     9p21.3   22053591   Intron   A/G             0.148   0.140   0.672   1.06   0.78-1.45   0.689   0.148   0.163   0.527   0.89   0.62-1.30   0.553
  rs1412832    CDKN2BAS   9     9p21.3   22077543   Intron   C/T             0.259   0.285   0.619   0.87   0.69-1.12   0.279   0.273   0.285   1.000   0.94   0.70-1.27   0.690
  rs6475606    CDKN2BAS   9     9p21.3   22081850   Intron   C/T             0.275   0.303   0.470   0.87   0.69-1.10   0.254   0.303   0.297   0.581   1.03   0.77-1.38   0.839
  rs1333040    CDKN2BAS   9     9p21.3   22083404   Intron   C/T             0.273   0.294   0.538   0.90   0.71-1.15   0.408   0.294   0.293   0.677   1.00   0.75-1.35   0.985
  rs1537370    CDKN2BAS   9     9p21.3   22084310   Intron   C/T             0.273   0.299   0.331   0.88   0.69-1.12   0.305   0.303   0.297   0.581   1.03   0.77-1.38   0.839
  rs10757274   CDKN2BAS   9     9p21.3   22096055   Intron   G/A             0.483   0.418   1.000   1.30   1.05-1.61   0.018   0.458   0.425   0.555   1.14   0.87-1.50   0.338
  rs1333042    CDKN2BAS   9     9p21.3   22103813   Intron   A/G             0.310   0.353   0.574   0.83   0.66-1.04   0.104   0.324   0.340   0.898   0.93   0.70-1.24   0.626

Chr: Chromosome; MAF: Minor allele frequency; HWE: Hardy-Weinberg equilibrium; OR: Odds ratio; 95% CI: 95% Confidence interval.

*P* values were calculated from Chi-square /Fisher\'s exact.

*P* \<0.05 indicates statistical significance.

We further assessed the association between each SNP and CHD risk using unconditional logistic regression analysis after adjusting for age. The results of genetic model analyses (codominant, dominant, recessive, log-additive) are presented in Table [2](#T2){ref-type="table"}. We identified that rs10757274 was associated with increased CHD risk in men under a codominant model (*P* = 0.042); a recessive model (GG *vs* AA+AG: OR = 1.70, 95% CI: 1.10-2.62, *P* = 0.016) and a log-additive model (OR = 1.34, 95% CI: 1.05-1.71, *P* = 0.019). Interestingly, rs10757274 was also associated with increased CHD risk in women under both a codominant model (*P* = 0.004) and a dominant model (AG+GG *vs* AA: OR = 2.26, 95% CI: 1.28-3.99, *P* = 0.004). Allele "G" of rs7865618 was also associated with increased CHD risk under a codominant model (*P* = 0.021). A similar trend was observed for rs7865618, which was associated with a 6.79-fold increased risk of CHD in women under a recessive model (GG *vs* AA+GA: OR = 8.10, 95% CI: 1.74-37.68, *P* = 0.006).

###### Genetic models analyses of the association between *CDKN2BAS* SNPs and CHD susceptibility in men and women

  SNP-ID       Model          Genotype                 Men                                      Women                                           
  ------------ -------------- ---------- ------------- ------------- ------------------ ------- ------------- ------------- ------------------- -------
  rs7865618    Codominant     A/A        227 (78.3%)   290 (75.3%)   1                          127 (77%)     240 (80%)     1                   0.021
                              G/A        59 (20.3%)    88 (22.9%)    0.80 (0.52-1.23)   0.430   30 (18.2%)    57 (19%)      1.07 (0.57-1.98)    
                              G/G        4 (1.4%)      7 (1.8%)      0.54 (0.13-2.18)           8 (4.8%)      3 (1%)        8.20 (1.76-38.35)   
               Dominant       A/A        227 (78.3%)   290 (75.3%)   1                          127 (77%)     240 (80%)     1                   
                              G/A-G/G    63 (21.7%)    95 (24.7%)    0.78 (0.52-1.18)   0.240   38 (23%)      60 (20%)      1.37 (0.77-2.45)    0.290
               Recessive      A/A-G/A    286 (98.6%)   378 (98.2%)   1                          157 (95.2%)   297 (99%)     1                   
                              G/G        4 (1.4%)      7 (1.8%)      0.57 (0.14-2.28)   0.420   8 (4.8%)      3 (1%)        8.10 (1.74-37.68)   0.006
               Log-additive   \-\--      \-\--         \-\--         0.78 (0.54-1.14)   0.200   \-\--         \-\--         1.58 (0.97-2.58)    0.068
  rs11790231   Codominant     G/G        217 (74.6%)   281 (73.6%)   1                          121 (73.3%)   208 (69.3%)   1                   0.520
                              A/G        62 (21.3%)    95 (24.9%)    0.99 (0.65-1.50)   0.380   39 (23.6%)    86 (28.7%)    0.74 (0.42-1.29)    
                              A/A        12 (4.1%)     6 (1.6%)      2.15 (0.71-6.52)           5 (3%)        6 (2%)        1.23 (0.28-5.36)    
               Dominant       G/G        217 (74.6%)   281 (73.6%)   1                          121 (73.3%)   208 (69.3%)   1                   
                              A/G-A/A    74 (25.4%)    101 (26.4%)   1.07 (0.72-1.60)   0.720   44 (26.7%)    92 (30.7%)    0.78 (0.45-1.33)    0.350
               Recessive      G/G-A/G    279 (95.9%)   376 (98.4%)   1                          160 (97%)     294 (98%)     1                   
                              A/A        12 (4.1%)     6 (1.6%)      2.15 (0.71-6.51)   0.160   5 (3%)        6 (2%)        1.33 (0.31-5.76)    0.700
               Log-additive   \-\--      \-\--         \-\--         1.14 (0.81-1.60)   0.450   \-\--         \-\--         0.85 (0.53-1.35)    0.490
  rs1412832    Codominant     T/T        161 (55.5%)   194 (50.5%)   1                          84 (50.9%)    153 (51%)     1                   0.760
                              T/C        108 (37.2%)   161 (41.9%)   0.76 (0.52-1.09)   0.250   72 (43.6%)    123 (41%)     1.02 (0.62-1.69)    
                              C/C        21 (7.2%)     29 (7.5%)     0.70 (0.36-1.37)           9 (5.5%)      24 (8%)       0.71 (0.27-1.90)    
               Dominant       T/T        161 (55.5%)   194 (50.5%)   1                          84 (50.9%)    153 (51%)     1                   
                              T/C-C/C    129 (44.5%)   190 (49.5%)   0.75 (0.53-1.06)   0.100   81 (49.1%)    147 (49%)     0.97 (0.60-1.57)    0.890
               Recessive      T/T-T/C    269 (92.8%)   355 (92.5%)   1                          156 (94.5%)   276 (92%)     1                   
                              C/C        21 (7.2%)     29 (7.5%)     0.79 (0.42-1.51)   0.480   9 (5.5%)      24 (8%)       0.70 (0.27-1.83)    0.470
               Log-additive   \-\--      \-\--         \-\--         0.80 (0.61-1.05)   0.110   \-\--         \-\--         0.92 (0.63-1.36)    0.680
  rs6475606    Codominant     T/T        156 (53.6%)   183 (47.7%)   1                          77 (46.7%)    146 (48.7%)   1                   0.920
                              C/T        110 (37.8%)   169 (44%)     0.73 (0.50-1.05)   0.210   76 (46.1%)    130 (43.3%)   0.91 (0.55-1.50)    
                              C/C        25 (8.6%)     32 (8.3%)     0.76 (0.40-1.43)           12 (7.3%)     24 (8%)       0.89 (0.36-2.23)    
               Dominant       T/T        156 (53.6%)   183 (47.7%)   1                          77 (46.7%)    146 (48.7%)   1                   
                              C/T-C/C    135 (46.4%)   201 (52.3%)   0.73 (0.52-1.04)   0.077   88 (53.3%)    154 (51.3%)   0.90 (0.56-1.47)    0.680
               Recessive      T/T-C/T    266 (91.4%)   352 (91.7%)   1                          153 (92.7%)   276 (92%)     1                   
                              C/C        25 (8.6%)     32 (8.3%)     0.88 (0.48-1.61)   0.670   12 (7.3%)     24 (8%)       0.94 (0.39-2.27)    0.880
               Log-additive   \-\--      \-\--         \-\--         0.81 (0.62-1.06)   0.120   \-\--         \-\--         0.93 (0.63-1.36)    0.700
  rs1333040    Codominant     T/T        156 (53.6%)   188 (49.1%)   1                          80 (48.5%)    148 (49.3%)   1                   0.930
                              T/C        111 (38.1%)   165 (43.1%)   0.78 (0.54-1.12)   0.380   73 (44.2%)    128 (42.7%)   0.91 (0.55-1.52)    
                              C/C        24 (8.2%)     30 (7.8%)     0.81 (0.43-1.55)           12 (7.3%)     24 (8%)       0.90 (0.36-2.24)    
               Dominant       T/T        156 (53.6%)   188 (49.1%)   1                          80 (48.5%)    148 (49.3%)   1                   
                              T/C-C/C    135 (46.4%)   195 (50.9%)   0.78 (0.55-1.11)   0.170   85 (51.5%)    152 (50.7%)   0.91 (0.56-1.48)    0.710
               Recessive      T/T-T/C    267 (91.8%)   353 (92.2%)   1                          153 (92.7%)   276 (92%)     1                   
                              C/C        24 (8.2%)     30 (7.8%)     0.91 (0.49-1.69)   0.760   12 (7.3%)     24 (8%)       0.94 (0.39-2.27)    0.880
               Log-additive   \-\--      \-\--         \-\--         0.85 (0.65-1.11)   0.230   \-\--         \-\--         0.93 (0.64-1.37)    0.720
  rs1537370    Codominant     T/T        156 (53.6%)   185 (48%)     1                          77 (46.7%)    146 (48.7%)   1                   0.920
                              C/T        111 (38.1%)   170 (44.2%)   0.73 (0.51-1.06)   0.240   76 (46.1%)    130 (43.3%)   0.91 (0.55-1.50)    
                              C/C        24 (8.2%)     30 (7.8%)     0.79 (0.41-1.51)           12 (7.3%)     24 (8%)       0.89 (0.36-2.23)    
               Dominant       T/T        156 (53.6%)   185 (48%)     1                          77 (46.7%)    146 (48.7%)   1                   
                              C/T-C/C    135 (46.4%)   200 (52%)     0.74 (0.53-1.05)   0.093   88 (53.3%)    154 (51.3%)   0.90 (0.56-1.47)    0.680
               Recessive      T/T-C/T    267 (91.8%)   355 (92.2%)   1                          153 (92.7%)   276 (92%)     1                   
                              C/C        24 (8.2%)     30 (7.8%)     0.91 (0.49-1.70)   0.760   12 (7.3%)     24 (8%)       0.94 (0.39-2.27)    0.880
               Log-additive   \-\--      \-\--         \-\--         0.82 (0.62-1.07)   0.150   \-\--         \-\--         0.93 (0.63-1.36)    0.700
  rs10757274   Codominant     A/A        82 (28.2%)    130 (33.8%)   1                          39 (23.6%)    102 (34%)     1                   0.004
                              A/G        137 (47.1%)   188 (48.8%)   1.16 (0.78-1.72)   0.042   101 (61.2%)   141 (47%)     2.60 (1.44-4.71)    
                              G/G        72 (24.7%)    67 (17.4%)    1.86 (1.13-3.05)           25 (15.2%)    57 (19%)      1.52 (0.72-3.23)    
               Dominant       A/A        82 (28.2%)    130 (33.8%)   1                          39 (23.6%)    102 (34%)     1                   
                              A/G-G/G    209 (71.8%)   255 (66.2%)   1.33 (0.91-1.93)   0.130   126 (76.4%)   198 (66%)     2.26 (1.28-3.99)    0.004
               Recessive      A/A-A/G    219 (75.3%)   318 (82.6%)   1                          140 (84.8%)   243 (81%)     1                   
                              G/G        72 (24.7%)    67 (17.4%)    1.70 (1.10-2.62)   0.016   25 (15.2%)    57 (19%)      0.81 (0.43-1.51)    0.500
               Log-additive   \-\--      \-\--         \-\--         1.34 (1.05-1.71)   0.019   \-\--         \-\--         1.31 (0.92-1.87)    0.130
  rs1333042    Codominant     G/G        139 (47.9%)   162 (42.6%)   1                          74 (44.9%)    130 (43.3%)   1                   0.810
                              G/A        122 (42.1%)   168 (44.2%)   0.88 (0.61-1.27)   0.120   75 (45.5%)    136 (45.3%)   0.87 (0.52-1.45)    
                              A/A        29 (10%)      50 (13.2%)    0.55 (0.31-0.97)           16 (9.7%)     34 (11.3%)    0.81 (0.36-1.84)    
               Dominant       G/G        139 (47.9%)   162 (42.6%)   1                          74 (44.9%)    130 (43.3%)   1                   
                              G/A-A/A    151 (52.1%)   218 (57.4%)   0.79 (0.56-1.12)   0.190   91 (55.1%)    170 (56.7%)   0.86 (0.53-1.39)    0.530
               Recessive      G/G-G/A    261 (90%)     330 (86.8%)   1                          149 (90.3%)   266 (88.7%)   1                   
                              A/A        29 (10%)      50 (13.2%)    0.59 (0.34-1.01)   0.050   16 (9.7%)     34 (11.3%)    0.87 (0.40-1.90)    0.730
               Log-additive   \-\--      \-\--         \-\--         0.78 (0.61-1.01)   0.058   \-\--         \-\--         0.89 (0.62-1.28)    0.530

OR: Odd ratio; 95% CI: 95% Confidence.

*P* values were calculated from the Wald test.

*P* \< 0.05 indicates statistical significance.

Linkage Disequilibrium (LD) analysis demonstrated that two SNPs (rs10757274 and rs1333042) in *CDKN2BAS* showed strong linkage (Figure [1](#F1){ref-type="fig"}). Furthermore, the haplotype AA (rs10757274 and rs1333042) was significantly associated with a decreased risk of CHD in men (OR = 0.72, 95% CI: 0.55 - 0.95, *P* = 0.022; Table [3](#T3){ref-type="table"}).

![Haplotype block map for the eight SNPs in *CDKN2BAS* in men\
Block 1 includes rs1412832, rs6475606, rs1333040 and rs1537370; Block 2 includes rs10757274 and rs1333042. The LD between two SNPs is standardized D\'.](oncotarget-07-82046-g001){#F1}

###### Haplotype frequencies and association with the risk of CHD in men

  Chr   Gene       SNPs                    Haplotype   F_A     F_U     OR (95% CI)          *P*-value
  ----- ---------- ----------------------- ----------- ------- ------- -------------------- -----------
  9     CDKN2BAS   rs10757274\|rs1333042   GG          0.481   0.415   1                    \-\--
                                           AA          0.309   0.350   0.72 (0.55 - 0.95)   0.022
                                           AG          0.208   0.232   0.75 (0.54 - 1.04)   0.083

F_A: Frequency in cases; F_U: Frequency in controls; OR: Odd ratio; 95% CI: 95% Confidence.

*P* values were calculated using the Wald test.

*P* \< 0.05 indicates statistical significance.

Additionally, we also investigated the associations between *CDKN2BAS* polymorphisms and CHD-related biochemical indicators, including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), creatinine (CRE), neutrophil (NEU), platelet distribution width (PDW) as shown in Table [4](#T4){ref-type="table"}. The levels of HLD-C with rs6475606 (*P* = 0.022) and rs1333040 (*P* = 0.045) in men, and rs1412832 (*P* = 0.017) in women, were different between groups. Levels of CRE with rs7865618 (*P* = 0.035) and rs1412832 (*P* = 0.015) in men, and rs11790231 and rs6475606 (*P* = 0.033) in women, were also different between groups. In addition, the levels of NEU with three SNPs (rs7865618: *P* = 0.037, rs11790231: *P* = 0.018 and rs6475606: *P* = 0.027) and the levels PDW with four SNPs (rs7865618: *P* = 0.029, rs1333040: *P* = 0.047, rs1537370: *P* = 0.020 and rs10757274: *P* = 0.047) were different between groups, but only in women.

###### Lipid levels according to genotype in men and women

  Sex     SNP-ID       Genotype (N)   TG                  TC                  HDL-C               LDL-C               CRE                   NEU                 PDW          
  ------- ------------ -------------- ----------- ------- ----------- ------- ----------- ------- ----------- ------- ------------- ------- ----------- ------- ------------ -------
  Men     rs7865618    CC(137)        1.70±0.11           3.90±0.09           1.20±0.02           1.84±0.08           86.82±1.75            5.24±0.27           14.54±0.25   
                       TT(19)         1.74±0.27   0.524   3.95±0.43   0.607   1.15±0.07   0.549   1.87±0.24   0.927   85.63±3.18    0.035   5.18±0.69   0.699   14.16±0.59   0.496
                       CT(119)        1.93±0.19           4.04±0.11           1.09±0.02           1.88±0.07           80.58±1.72            5.56±0.29           14.11±0.27   
          rs11790231   GG(4)          1.54±0.46           3.54±0.77           1.00±0.01           1.75±0.52           74.63±9.56            4.67±0.63           13.03±1.11   
                       AA(217)        1.77±0.12   0.752   3.96±0.08   0.745   1.10±0.02   0.644   1.87±0.06   0.953   84.50±1.38    0.546   5.22±0.20   0.210   14.22±0.20   0.277
                       GA(53)         1.95±0.20           4.00±0.16           1.08±0.04           1.84±0.09           82.90±2.22            6.02±0.52           14.82±0.39   
          rs1412832    GG(203)        1.79±0.12           3.95±0.08           1.10±0.02           1.86±0.06           83.94±1.33            5.57±0.23           14.41±0.20   
                       AA(12)         1.46±0.15   0.659   3.80±0.26   0.803   0.99±0.06   0.281   1.88±0.20   0.994   99.43±11.89   0.015   5.42±0.81   0.161   12.67±0.74   0.186
                       AG(60)         1.92±0.17           4.03±0.17           1.10±0.03           1.86±0.11           81.30±1.59            4.68±0.33           14.28±0.36   
          rs6475606    CC(20)         1.76±0.24           3.64±0.25           0.95±0.04           1.72±0.13           79.66±4.68            6.02±1.05           14.00±0.61   
                       TC(101)        1.78±0.15   0.979   4.05±0.13   0.371   1.12±0.03   0.022   1.91±0.08   0.651   84.30±2.00    0.613   5.76±0.30   0.131   14.11±0.28   0.519
                       TT(153)        1.82±0.15           3.95±0.09           1.10±0.02           1.85±0.08           84.36±1.52            5.05±0.24           14.50±0.24   
          rs1333040    CC(24)         1.77±0.20           3.78±0.22           0.98±0.05           1.79±0.13           86.96±6.80            5.97±0.90           13.51±0.59   
                       TT(147)        1.79±0.15   0.992   3.94±0.09   0.638   1.11±0.02   0.045   1.86±0.08   0.907   84.74±1.55    0.501   5.12±0.25   0.320   14.61±0.25   0.148
                       CT(104)        1.81±0.15           4.02±0.13           1.11±0.03           1.88±0.08           82.46±1.63            5.59±0.29           14.09±0.26   
          rs1537370    CC(23)         1.64±0.16           3.68±0.21           0.98±0.05           1.79±0.13           86.34±7.09            6.05±0.93           13.43±0.62   
                       TC(105)        1.84±0.15   0.867   4.04±0.13   0.410   1.11±0.03   0.055   1.88±0.08   0.915   82.62±1.62    0.592   5.57±0.29   0.299   14.10±0.25   0.134
                       TT(147)        1.79±0.15           3.94±0.09           1.11±0.02           1.86±0.08           84.74±1.55            5.12±0.25           14.61±0.25   
          rs10757274   CC(23)         1.64±0.16           3.68±0.21           0.98±0.05           1.79±0.13           86.34±7.09            6.05±0.93           13.43±0.62   
                       TT(147)        1.79±0.15   0.867   3.94±0.09   0.410   1.11±0.02   0.055   1.86±0.08   0.915   84.74±1.55    0.592   5.12±0.25   0.299   14.61±0.25   0.134
                       CT(105)        1.84±0.15           4.04±0.13           1.11±0.03           1.88±0.08           82.62±1.62            5.57±0.29           14.10±0.25   
          rs1333042    GG(69)         1.74±0.15           3.95±0.13           1.15±0.03           1.94±0.15           84.05±1.95            4.85±0.36           14.49±0.35   
                       AA(78)         1.69±0.16   0.650   3.88±0.15   0.766   1.07±0.03   0.098   1.81±0.09   0.644   82.23±2.22    0.591   5.71±0.40   0.258   14.24±0.31   0.856
                       AG(128)        1.90±0.17           4.01±0.10           1.08±0.02           1.84±0.06           85.10±1.84            5.43±0.26           14.28±0.26   
  Women   rs7865618    CC(78)         1.88±0.17           4.33±0.11           1.16±0.03           1.96±0.07           72.77±1.89            4.01±0.24           13.77±0.36   
                       TT(14)         2.09±0.42   0.320   4.78±0.30   0.213   1.24±0.07   0.264   2.24±0.23   0.383   70.62±4.72    0.849   5.94±1.02   0.037   16.28±0.82   0.029
                       CT(62)         1.62±0.09           4.23±0.14           1.22±0.03           2.05±0.10           70.82±3.47            4.32±0.34           13.97±0.41   
          rs11790231   GG(7)          1.41±0.13           4.49±0.28           1.12±0.10           2.15±0.12           89.85±25.84           6.83±0.87           14.08±1.01   
                       AA(120)        1.72±0.12   0.119   4.24±0.10   0.163   1.19±0.02   0.759   1.99±0.07   0.615   71.83±1.53    0.033   4.14±0.24   0.018   14.09±0.31   0.986
                       GA(28)         2.22±0.26           4.66±0.22           1.20±0.05           2.12±0.14           66.94±1.65            4.28±0.38           13.98±0.57   
          rs1412832    GG(113)        1.84±0.13           4.35±0.11           1.16±0.02           2.02±0.07           71.43±2.13            4.44±0.25           13.69±0.31   
                       AA(5)          1.59±0.13   0.769   5.26±0.42   0.082   1.39±0.12   0.017   2.70±0.35   0.079   67.38±4.81    0.788   4.27±0.99   0.490   14.90±1.40   0.051
                       AG(37)         1.69±0.15           4.15±0.13           1.26±0.04           1.94±0.11           73.57±3.07            3.86±0.35           15.13±0.49   
          rs6475606    CC(8)          2.22±0.44           5.00±0.21           1.27±0.08           2.45±0.21           89.42±22.61           6.44±0.98           14.23±0.92   
                       TC(68)         1.91±0.20   0.291   4.33±0.13   0.179   1.19±0.03   0.681   1.99±0.08   0.212   69.15±1.62    0.033   3.97±0.28   0.027   13.38±0.37   0.065
                       TT(79)         1.65±0.09           4.26±0.12           1.19±0.03           2.01±0.08           72.22±1.96            4.35±0.30           14.63±0.38   
          rs1333040    CC(11)         1.99±0.34           4.82±0.19           1.23±0.07           2.33±0.17           82.56±17.23           5.93±0.82           14.18±0.80   
                       TT(73)         1.62±0.09   0.276   4.25±0.13   0.248   1.19±0.03   0.838   2.00±0.09   0.326   72.20±2.13    0.172   4.28±0.31   0.068   14.73±0.40   0.047
                       CT(71)         1.94±0.20           4.34±0.12           1.18±0.03           1.19±0.08           69.74±1.50            4.05±0.28           13.39±0.36   
          rs1537370    CC(11)         1.99±0.34           4.82±0.19           1.23±0.07           2.33±0.17           82.56±17.23           5.93±0.82           14.18±0.80   
                       TC(69)         1.95±0.20   0.263   4.36±0.12   0.221   1.19±0.03   0.850   2.00±0.08   0.327   69.40±1.55    0.152   3.96±0.27   0.050   13.27±0.36   0.020
                       TT(75)         1.62±0.09           4.23±0.13           1.19±0.03           2.00±0.09           72.42±2.06            4.36±0.31           14.78±0.39   
          rs10757274   CC(11)         1.99±0.34           4.82±0.19           1.23±0.07           2.33±0.17           82.56±17.23           5.93±0.82           14.18±0.80   
                       TT(73)         1.62±0.09   0.276   4.25±0.13   0.248   1.19±0.03   0.838   2.00±0.09   0.326   72.20±2.13    0.172   4.28±0.31   0.068   14.73±0.40   0.047
                       CT(71)         1.94±0.20           4.34±0.12           1.18±0.03           1.19±0.08           69.74±1.50            4.05±0.28           13.39±0.36   
          rs1333042    GG(24)         1.62±0.18           3.95±0.23           1.24±0.06           1.83±0.16           70.55±3.08            4.13±0.55           15.27±0.67   
                       AA(36)         1.99±0.21   0.528   4.52±0.14   0.116   1.17±0.03   0.554   2.16±0.11   0.223   74.91±5.50    0.608   4.68±0.44   0.584   13.45±0.60   0.113
                       AG(95)         1.77±0.14           4.36±0.11           1.19±0.03           2.02±0.07           70.93±1.70            4.20±0.26           14.03±0.31   

TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; CRE: Creatinine; NEU: Neutrophil;

PDW: Platelet distribution width

DISCUSSION {#s3}
==========

The goal of our case-control study was to explore the associations of eight polymorphisms in *CDKN2BAS* with the risk of CHD in a Han Chinese population. We found that rs10757274 was associated with an increased risk of CHD both in men and women. However, rs7865618 was correlated with an increased risk of CHD only in women. In addition, we also found that the haplotype "AA" (rs10757274 and rs1333042) of *CDKN2BAS* was associated with a decreased CHD risk in men.

Previous studies have demonstrated that *CDKN2BAS* transcript levels show a strong correlation with the severity of atherosclerosis. In addition, the modulation of *CDKN2BAS* expression influences CHD susceptibility. The function of *CDKN2BAS* is unknown, but it regulates the expression of *CDKN2A* and *CDKN2B*, which encode cyclin-dependent kinase inhibitors 2A and 2B, indicating a regulatory role for *CDKN2BAS* in cellular proliferation. Polymorphisms at the 9p21 region may induce higher expression of the *CDKN2BAS* transcript, thereby inhibiting the expression of *CDKN2A* and *CDKN2B*.

Several studies have demonstrated a strong association of rs10757274 with CHD in Pakistani \[[@R9]\], Caucasian \[[@R15]\], and South-West Iranian \[[@R16]\] population. Our results are consistent with these previous findings d. However, one previous study found no association of rs10757274 with CHD in a Han Chinese population (Shenzhen) \[[@R17]\].The differences between our study and this study are likely due to differences in the two study populations. How rs10757274 affects the risk of CHD is unclear, but this SNP may regulate the expression of *EU741058* and *p16INK4a*, which modulate the risk of developing CHD \[[@R18]\]. Some studies have also suggested that rs10757274impairs the mechanical properties of the arterial wall and thus influences vascular diseases \[[@R19]\].

It was previously shown that rs1333042 is associated with the risk of CHD in the Han Chinese \[[@R20], [@R21]\] and Saudi populations \[[@R7]\], which is inconsistent with our findings. The differences in these studies may be explained by ethnic differences, environment, or lifestyle that also affected the development of CHD. We also observed that rs7865618 was associated with CHD risk in women. However, this SNP has previously only been found to interact with other SNPs to affect the development of CHD \[[@R6]\]. In future studies, we will verify our results using a larger sample size.

We didn\'t observe any association between rs1333040 and the risk of CHD, which is consistent with the studies by Cao et al. \[[@R21]\] and Golabgir Khademi et al. \[[@R22]\]. This SNP was significantly associated with the risk of CHD in a Northern Indian population \[[@R23]\] and in African American women \[[@R24]\]. Genetic variation and differences in life styles among populations probably explain the population disparities in the association of this SNP and susceptibility to CHD. Furthermore, recent studies have reported that the levels of TG, TC, HDL-C, LDL-C, CRE, NEU and PDW effectively predict the risk of CHD \[[@R25]--[@R28]\]. Interestingly, we also demonstrated that SNPs in *CDKN2BAS* were correlated with the levels of these biochemical indicators and differed between cases and controls.

Several limitations should be acknowledged in the present study. First, the sample size was relatively small and the participants were limited to Chinese ethnicity. Second, there were differences in some clinical characteristics between the patients and controls. Although several confounders have been adjusted for the statistical analyses, we could not completely eliminate the potential influences of these factors on the results. Finally, the biological mechanism of genetic variants in *CDKN2BAS* was not investigated in this study. It will be important to follow up and validate our findings with larger sample sizes.

In conclusion, our results suggest that, in a Chinese Han population, rs10757274 in *CDKN2BAS* is associated with the risk of CHD both in men and women, rs7865618 is correlated with an increased risk of CHD only in women, and the haplotype AA (rs10757274 and rs1333042) of *CDKN2BAS* is associated with a decreased CHD risk in men. Thus, these SNPs could have clinical importance as pre-diagnostic markers. Further study is required to determine the functional effects of these SNPs and validate these findings in larger populations.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Written informed consent was obtained from all study participants before the interview. This study protocol was approved by the Ethical Committee of the Yanan University Affiliated Hospital and the First Affiliated Hospital of Xi\'an Jiaotong University, and complied with the World Medical Association Declaration of Helsinki.

Study participants {#s4_2}
------------------

The study included 676 men (291 CHD cases with a mean age of 60 years and 385 healthy controls with a mean age of 48 years) and 465 women (165 CHD cases with a mean age of 64 years and 300 healthy controls with a mean age of 50 years). All CHD cases were recruited from the Cardiovascular Internal Medicine Department of Yanan University Affiliated Hospital between February 2014 and April 2015. The 685 healthy controls were randomly selected from physical examination center of the same hospital during the same period. The inclusion and exclusion criteria for participants were as follows: First, all subjects were of the ethnic Han origin and not related to each other. Second, all participants diagnosis we based on standardized electrocardiogram, echocardiography, blood tests and coronary angiography and judged by two or three independent cardiologists. Third, all individuals were excluded from the study if they had other cardiac diseases (congenital heart disease, cardiomyopathy, or rheumatic heart disease), diabetes, hypertension, or severe liver or kidney disease.s, Patients who had previously received angioplasty, intravenous thrombolysis, coronary artery stents, or coronary artery bypass surgery were also excluded. Basic characteristics of all enrolled controls were collected with a standard epidemiological questionnaires conducted by well-trained interviewers. The cases information was collected through consultation with treating physicians or from medical chart review. Peripheral venous blood (5 ml) was collected from each participant using vacutainer tubes containing ethylene diamine tetra-acetic acid (EDTA) and then stored at -80°C. A clinical examination at which a blood sample was drawn for routine analysis of blood levels, biochemical tests, coagulation function, and genetic analyses.

SNP selection and genotyping {#s4_3}
----------------------------

The eight SNPs in *CDKN2BAS* (rs7865618, rs1179023, rs1412832, rs6475606, rs1333040, rs1537370, rs10757274 and rs1333042) were selected from previous reports for their association with CHD \[[@R9], [@R21], [@R23], [@R29], [@R30]\]. The minor allele frequency of each SNP was \> 5% in the HapMap of the Chinese Han Beijing (CHB) population. Genomic DNA was extracted from whole blood using the GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacturer\'s protocol (GoldMag. Co. Ltd., Xi\'an, China). DNA concentration and purity were evaluated using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, USA). Polymerase chain reaction (PCR) and extension primers for the SNPs were designed using the Sequenom MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CaliforniaCA, USA). Genotyping was performed using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) according to the standard instructions. Sequenom Typer 4.0 software was used for data management and analyses.

Statistical analysis {#s4_4}
--------------------

SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel (Microsoft Corp., Redmond, WA, USA) were used for statistical analyses. Genotypic frequencies in controls (men and women) were tested for departure from HWE using a Fisher\'s exact test. The allelic frequencies were compared between cases and controls by Chi-squared test/Fisher\'s exact test, and the relative risk was estimated by odd ratios (ORs) and 95% confidence intervals (CIs). The genetic model analyses (codominant, dominant, recessive, log-additive) were applied using PLINK software to assess the significance of SNPs. ORs and 95% CIs were calculated using unconditional logistic regression analysis with adjustment for age. The *p* values were calculated with the Wald test. Haploview software (version 4.2) was used for analyses of the pairwise linkage disequilibrium (LD), haplotype structure and genetic association at polymorphism loci. All *p* values were two-sided, and *p* \< 0.05 is considered statistically significant.

We thank all authors for their contributions and support. We are grateful to all participants in the study who provided blood samples. We would also like to thank the hospital staff who contributed to data collection for this study.

**CONFLICTS OF INTEREST**

The authors declare that there are no conflicts of interest.

**GRANT SUPPORT**

This work is supported by the National Natural Science Foundations (No. 81200098) and the Key Science and Technology Program of Shaanxi Province (No. 2014K11-03-04-06).
